Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice.
(2012) Clinical and Experimental Pharmacology & Physiology — Vol. 39, n° 6, p. 544-550 (2012)
Files
2012_Van_Hul_Clin_Exp_Pharmacol_Physiol_544-550.pdf
Open Access - Adobe PDF
- 549.78 KB
Details
- Authors
- Abstract
- 1. Because the development of adipose tissue involves remodelling of the extracellular matrix (ECM), which requires matrix metalloproteinase (MMP) activity, we examined whether MMP inhibitors may have the potential to affect adipose tissue mass in obese mice. 2. Administration of the relatively gelatinase-specific MMP inhibitor tolylsam ((R)-3-methyl-2-[4-(3-p-tolyl-[1,2,4]oxadiazol-5-yl)-benzenesulphonylamino]-butyric acid; 100 mg/kg per day) for 7 weeks to obese wild-type mice on a high-fat diet resulted in significantly lower bodyweight (P < 0.05), lower subcutaneous (SC) and gonadal (GON) adipose tissue mass (both P < 0.05) and smaller adipocytes in both SC (P < 0.005) and GON (P < 0.0005) adipose tissues. 3. Magnetic resonance imaging confirmed a lower total body fat content in tolylsam-treated mice (P < 0.0005). In addition, tolylsam treatment of wild-type mice was associated with a marked enhancement in metabolic rate. 4. Electron microscopy analysis of tissue sections at the end of the 7 week feeding period revealed significantly higher collagen accumulation in the ECM of SC adipose tissues of tolylsam-treated mice (P < 0.001). 5. Thus, the relatively gelatinase-specific MMP inhibitor tolylsam has the potential to affect fat tissue growth in obese mice.
- Affiliations
KU Leuven Center for Molecular and Vascular Biology
Citations
Van Hul, M., Lupu, F., Dresselaers, T., Buyse, J., & Lijnen, H. R. (2012). Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice. Clinical and Experimental Pharmacology & Physiology, 39(6), 544-550. https://doi.org/10.1111/j.1440-1681.2012.05714.x (Original work published 2012)